Venture Map · Round
CONNECTA Therapeutics — Series A · €3.1M
Announced 2026-09-10 · Barcelona · Biotech / CNS therapeutics
The Barcelona Science Park biotech raised €3.1M led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth fund, with existing backers Inveready, CDTI Innvierte and Prous Institute. The money completes the Phase IIa trial of CTH120, a TrkB neuroplasticity modulator for Fragile X syndrome, with topline data expected mid-2027.
RoundSeries A
Amount€3.1M
LeadClave Capital
Date2026-09-10
CityBarcelona
SectorBiotech / CNS therapeutics
The company
Investors 4
CClave Capital
clave.capital
CCDTI Innvierte
www.cdti.es
IInveready
inveready.com
P
Prous Institute for Biomedical Research